Overview

A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

Status:
Completed
Trial end date:
2011-06-24
Target enrollment:
0
Participant gender:
All
Summary
This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Criteria
Inclusion Criteria:

- Diagnosis of open-angle glaucoma or ocular hypertension

- No use of Lumigan® in the past 3 months

Exclusion Criteria:

- Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery
within the past 3 months